Suppr超能文献

使用表位特异性免校准浓度分析克服蛋白质活性的批次间差异

Overcoming Lot-to-Lot Variability in Protein Activity Using Epitope-Specific Calibration-Free Concentration Analysis.

作者信息

Harvey Ian B, Chilewski Shannon D, Bhosale Devyani, Tobia Sarah E, Gray Christopher, Gleason Carol, Haulenbeek Jonathan

机构信息

Translational Sciences and Diagnostics, Bristol-Myers Squibb, Princeton, New Jersey 08540, United States.

Global Biometrics and Data Sciences, Bristol-Myers Squibb, Princeton, New Jersey 08540, United States.

出版信息

Anal Chem. 2024 Apr 23;96(16):6275-6281. doi: 10.1021/acs.analchem.3c05607. Epub 2024 Apr 10.

Abstract

Concentration determination is a fundamental hallmark of protein reagent characterization, providing a means to ensure reproducibility and unify measurements from various assays. However, lot-to-lot differences in protein activity often still occur, leading to uncertainty in the accuracy of downstream measurements. Here, we postulate that those differences are caused by a misrepresentation of the protein concentration as measured by traditional total protein techniques, which can include multiple types of inactive protein species. To overcome this, we developed a standardized method to quantify a protein's active concentration via calibration-free concentration analysis (CFCA). As a pilot study, we compare the biophysical and immunoassay responses from three batches of recombinant soluble lymphocyte-activation gene 3 (sLAG3), as defined by either their total or active concentrations. Defining the sLAG3 reagents by their assay-specific concentration improved consistency in reported kinetic binding parameters and decreased immunoassay lot-to-lot coefficients of variation (CVs) by over 600% compared to the total protein concentration. These findings suggest that the total concentration of a protein reagent may not be the ideal metric to correlate in-assay signals between lots, and by instead quantifying the concentrations of a reagent's assay-specific epitopes, CFCA may prove a useful tool in overcoming lot-to-lot variability.

摘要

浓度测定是蛋白质试剂表征的一个基本特征,它提供了一种确保可重复性并统一来自各种检测方法测量结果的手段。然而,蛋白质活性的批次间差异仍然经常出现,导致下游测量准确性的不确定性。在这里,我们推测这些差异是由传统总蛋白技术测量的蛋白质浓度的错误表征引起的,传统总蛋白技术可能包括多种类型的无活性蛋白种类。为了克服这一问题,我们开发了一种标准化方法,通过无校准浓度分析(CFCA)来量化蛋白质的活性浓度。作为一项初步研究,我们比较了三批重组可溶性淋巴细胞激活基因3(sLAG3)的生物物理和免疫分析响应,这些sLAG3是根据它们的总浓度或活性浓度定义的。与总蛋白浓度相比,根据特定检测方法的浓度定义sLAG3试剂提高了报告的动力学结合参数的一致性,并使免疫分析批次间变异系数(CV)降低了600%以上。这些发现表明,蛋白质试剂的总浓度可能不是关联批次间检测信号的理想指标,相反,通过量化试剂特定检测表位的浓度,CFCA可能是克服批次间变异性的有用工具。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9516/11044105/71e4772b69c4/ac3c05607_0001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验